<DOC>
	<DOCNO>NCT03023423</DOCNO>
	<brief_summary>The purpose study compare overall response rate ( ORR ) non-small cell lung cancer ( NSCLC ) participant treat daratumumab combination atezolizumab versus atezolizumab alone .</brief_summary>
	<brief_title>A Study Daratumumab Combination With Atezolizumab Compared With Atezolizumab Alone Participants With Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Have histologically cytologically confirm advanced metastatic nonsmall cell lung cancer ( NSCLC ) ( Stage IIIb IV ) Measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 response criterion Known program deathligand 1 ( PDL1 ) tumor status determine immunohistochemistry ( IHC ) assay perform central laboratory tissue obtain Screening A woman childbearing potential must negative highly sensitive serum ( betahuman chorionic gonadotropin [ beta hCG ] ) Screening within 14 day prior study drug administration Received follow prescribed medication therapy past : 1 . Anticluster differentiation ( CD ) 38 therapy , include daratumumab 2 . CD137 agonist , immune checkpoint inhibitor include limited anticytotoxicTlymphocyteassociated antigen 4 ( CTLA4 ) , antiPD1 , antiPDL1 therapy Known seropositive human immunodeficiency virus ( HIV ) Prior allogeneic bone marrow transplantation solid organ transplant History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Active hepatitis B ( define positive test hepatitis B surface antigen [ HBsAg ] antibodies hepatitis B surface core antigens [ antiHBs antiHBc , respectively ] ) hepatitis C ( anti HCV antibody positive HCVRibonucleic acid [ RNA ] quantitation positive )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>